Severe myoclonic epilepsy of infancy is a rare condition affecting babies and young children that requires careful treatment to control seizures and support healthy development. Understanding the available options—from proven medications to emerging therapies being tested in research studies—can help families navigate this challenging diagnosis with greater confidence.

Understanding Treatment Goals in Severe Myoclonic Epilepsy of Infancy

When a child is diagnosed with severe myoclonic epilepsy of infancy, also known as Dravet syndrome, the main goal of treatment is to reduce the frequency and severity of seizures while supporting the child’s overall development and quality of life. This condition differs from the milder form called myoclonic epilepsy of infancy, as it typically causes more intense and difficult-to-control seizures that can have lasting effects on a child’s growth and abilities.^[5]

Treatment approaches must be tailored to each individual child because the condition affects children differently. Some may respond well to certain medications, while others may need a combination of therapies. The timing of treatment is also important—starting appropriate therapy early can help prevent some of the complications associated with prolonged or frequent seizures. Medical teams consider factors such as the child’s age, the types of seizures they experience, how often seizures occur, and any developmental delays or other health concerns when planning treatment.^[7]

Standard treatments recommended by medical societies have been used for many years and form the foundation of care. However, because severe myoclonic epilepsy of infancy often resists conventional treatment, researchers continue to explore new therapeutic approaches through clinical trials. These studies aim to find better ways to control seizures and improve outcomes for affected children.^[10]

Standard Medications and Therapies

The cornerstone of treating severe myoclonic epilepsy of infancy involves anticonvulsant medications—drugs designed to reduce abnormal electrical activity in the brain that causes seizures. The choice of medication depends on the specific types of seizures the child experiences and how their body responds to treatment.^[9]

Valproic acid, also known as sodium valproate, has traditionally been one of the primary medications used. This drug works by increasing the amount of a brain chemical called GABA that helps calm nerve activity. Valproic acid can be effective in controlling various seizure types, but it requires careful monitoring because it can affect the liver and other organs. Blood tests are typically performed regularly to ensure the medication is working properly and not causing harmful side effects.^[10]

Benzodiazepines represent another class of medications commonly prescribed for this condition. Clobazam and clonazepam are examples from this group that help reduce seizure activity by enhancing the calming effects of GABA in the brain. These medications are often used alongside valproic acid, as the combination can be more effective than either drug alone. However, benzodiazepines can cause drowsiness, and some children may develop tolerance over time, meaning the medication becomes less effective with prolonged use.^[9]

Stiripentol is a newer medication specifically approved for use in children with Dravet syndrome who are already taking clobazam. This drug was developed to work together with other seizure medications to enhance their effectiveness. Stiripentol helps the body process clobazam more slowly, allowing the medication to work longer and more effectively. Clinical guidelines recommend stiripentol as part of combination therapy rather than as a single treatment. Research has shown that adding stiripentol to existing treatment regimens can significantly reduce seizure frequency in some children.^[9][10]

Treatment duration varies considerably from child to child. Some children may need to continue medications for many years, while others might eventually be able to reduce or stop treatment if seizures come under control. However, severe myoclonic epilepsy of infancy is often described as medically refractory, meaning it doesn’t respond well to medications. This resistance to treatment means many children require multiple medications used together, a strategy called polytherapy.^[9]

Side effects are an important consideration with all seizure medications. Common side effects can include drowsiness, dizziness, changes in appetite, weight gain or loss, and changes in behavior or mood. More serious side effects, though less common, may include liver problems, blood disorders, or allergic reactions. Regular medical monitoring helps identify any problems early so adjustments can be made to the treatment plan.^[10]

Beyond medications, supportive therapies play an important role. Dietary modifications, particularly the ketogenic diet—a high-fat, low-carbohydrate eating plan—have shown promise in reducing seizure frequency in some children with difficult-to-control epilepsy. This diet changes the way the body uses energy, producing substances called ketones that may help stabilize brain activity. The diet must be carefully supervised by healthcare professionals and nutritionists to ensure children receive adequate nutrition for growth and development.^[9]

Additional approaches may include avoiding triggers that can provoke seizures, such as high fevers, hot baths, or physical overexertion. Maintaining good sleep habits and minimizing stress can also help reduce seizure frequency. Families often need to implement safety measures at home to protect children during seizures, such as padding hard surfaces and supervising bathing closely.^[5]

Emerging Treatments in Clinical Research

Because standard treatments don’t always adequately control seizures in severe myoclonic epilepsy of infancy, researchers are actively investigating new therapeutic approaches. Clinical trials represent the pathway through which experimental treatments are tested for safety and effectiveness before becoming widely available.^[9]

One of the most significant recent developments is cannabidiol, a compound derived from cannabis plants that doesn’t produce the “high” associated with marijuana use. A purified formulation of cannabidiol, marketed under the name Epidiolex, has been approved for treating seizures associated with Dravet syndrome in children as young as six months. This medication works through mechanisms that are still being studied but appear to involve multiple pathways in the brain that help control abnormal electrical activity.^[9]

The approval of cannabidiol came after rigorous clinical trials, particularly Phase III studies that compared the medication to placebo in large groups of patients. In international research involving patients with Dravet syndrome, those receiving cannabidiol experienced significant reductions in seizure frequency compared to those receiving inactive placebo. The medication was added to patients’ existing treatment regimens over 14 weeks, and results showed meaningful improvements in seizure control. These trials demonstrated that cannabidiol could reduce drop seizures—sudden seizures that cause a person to fall—by approximately 40% when given at higher doses, compared to about 17% reduction with placebo. Side effects were generally manageable and included drowsiness, decreased appetite, diarrhea, and elevated liver enzymes in some patients.^[9]

Understanding clinical trial phases helps families grasp where different treatments stand in the development process. Phase I trials focus primarily on safety, testing new treatments in small groups to identify potential side effects and determine safe dosage ranges. Phase II trials involve larger groups and begin to evaluate whether the treatment actually works for its intended purpose while continuing to monitor safety. Phase III trials involve even larger patient populations and compare the new treatment directly against current standard treatments or placebo to definitively establish effectiveness and safety. Only after successfully completing all three phases can a treatment be submitted for regulatory approval and become available for general use.^[9]

Other innovative approaches being explored include medications that target specific genetic mutations underlying the condition. Research has identified that mutations in the SCN1A gene, which provides instructions for making sodium channels in brain cells, are responsible for 70-90% of Dravet syndrome cases. These sodium channels are like gates that control electrical signals in the brain. When the gene is mutated, the gates don’t work properly, leading to abnormal electrical activity and seizures. Scientists are working on therapies designed to compensate for these specific genetic defects, though these approaches are still in early research stages.^[5]

Gene therapy—treatments that aim to correct or compensate for faulty genes—represents another frontier in research. While these therapies are not yet available for severe myoclonic epilepsy of infancy, the concept involves delivering working copies of genes or using other techniques to overcome the effects of mutations. This approach holds promise for the future but requires extensive testing to ensure safety and effectiveness.

Neuromodulation techniques are also being studied. These include devices that deliver electrical stimulation to nerves or brain regions to help control seizures. While these approaches have been used in other forms of epilepsy, their application to severe myoclonic epilepsy of infancy is still being investigated. Examples include vagus nerve stimulation, which uses a device implanted under the skin to send regular electrical pulses to the brain via the vagus nerve in the neck.^[9]

Clinical trials for severe myoclonic epilepsy of infancy are conducted in various locations around the world, including specialized epilepsy centers in the United States, Europe, and other regions. Eligibility for trials typically depends on factors such as the child’s age, seizure type and frequency, current medications, and confirmation of the diagnosis. Families interested in clinical trials can discuss options with their child’s medical team, who can help determine if participation might be appropriate and beneficial.

It’s important to understand that experimental treatments carry uncertainties. Even if a therapy shows promise in early studies, it may not prove effective or safe in larger trials. Participation in clinical trials involves potential risks, but it also contributes to advancing knowledge that may benefit future patients. Trial participants receive close monitoring and specialized care throughout the study period.

Most Common Treatment Methods

• Anticonvulsant Medications
  • Valproic acid (sodium valproate) as a primary medication to reduce abnormal brain electrical activity
  • Benzodiazepines such as clobazam or clonazepam to enhance calming brain chemicals
  • Stiripentol used in combination with clobazam for enhanced effectiveness
  • Combination therapy with multiple medications when single drugs prove insufficient
• Cannabidiol-Based Therapy
  • Purified cannabidiol formulation (Epidiolex) approved for children six months and older
  • Works through multiple brain pathways to control abnormal electrical activity
  • Added to existing medication regimens to reduce seizure frequency
  • Demonstrated significant reductions in seizure frequency in Phase III clinical trials
• Dietary Modifications
  • Ketogenic diet involving high-fat, low-carbohydrate eating patterns
  • Produces ketones that may help stabilize brain activity
  • Requires careful supervision by healthcare professionals and nutritionists
  • Shown promise in reducing seizures in some children with difficult-to-control epilepsy
• Supportive Care Measures
  • Avoiding triggers such as high fevers, hot baths, and physical overexertion
  • Maintaining good sleep habits to reduce seizure frequency
  • Implementing safety measures at home to protect during seizures
  • Regular monitoring through blood tests and medical check-ups